



**Theoretical and Physical Chemistry Institute  
National Hellenic Research Foundation  
Vass. Constantinou 48, Athens**

**ONLINE LECTURE**

**“Macromolecular Powder Diffraction: Ready for  
Genuine Biological Problems”**

**Prof. I. Margiolaki**

**Department of Biology,**

**University of Patras,**

**Greece**

**Friday, November 26, 2021, 10:45**

**Link: [Click here to join the lecture](#)**


**Passcode: 085732**

## Macromolecular Powder Diffraction: Ready for Genuine Biological Problems

Margiolaki I.

Department of Biology, Section of Genetics, Cell Biology and Development, University of Patras, GR-26500 Patras, Greece.

Web: <https://sites.google.com/view/margiolaki-biology-upat/home>, E-mail: [imargiola@upatras.gr](mailto:imargiola@upatras.gr)



### Ligand identification via XRPD.

Identification of 6 m-cresol hydrophobic binding sites in a new monoclinic form of Human Insulin. [3, 7, 8, 9].

Knowledge of 3D structures of biological molecules plays a major role in both understanding important processes of life and developing pharmaceuticals. Among several methods available for structure determination, macromolecular X-ray powder diffraction (XRPD) [1] has transformed over the past decade from an impossible dream to a respectable method. XRPD can be employed in biosciences for various purposes such as observing phase transitions [2], characterizing bulk pharmaceuticals [3], determining structures via the molecular replacement method, detecting ligands in protein–ligand complexes (4), as well as in situ detection of novel protein crystal forms upon controlled relative humidity variation using laboratory XRPD [5]. This presentation aims to provide necessary elements of theory and current methods, along with practical explanations, available software packages and highlighted case studies. We will demonstrate the value of in-house and synchrotron XRPD as an analysis tool in industrial protein-based drug screening [6], and its potential to help troubleshooting the production process and to provide information for further refining the manufacturing of pharmaceuticals. Selected examples will be presented regarding studies of pharmaceutical proteins and their complexes with organic ligands including Human Insulin [3, 9], Urate Oxidase [10] as well as peptide drugs [11].

1. Karavassili F. & Margiolaki I., *Protein & Peptide Letters*, **23**, 232 (2016).
2. Fili S. et al., *IUCrJ*, **4**, 2, 534 (2015).
3. Karavassili et al., *Biomolecules*, **7** (3), 63, (2017) ([OPEN ACCESS](#)).
4. Margiolaki I. et al., *J. Am. Chem. Soc.* **129**, 11865 (2007); Karavassili et al., *Acta Cryst. D76*, 4, 375-384 (2020).
5. Trampari S. et al., *Journal of Applied Crystallography* **51**, 1 (2018); Logotheti et al., *JAC*, **52**, 816-822 (2019).
6. ESRF Industrial case studies <http://www.esrf.eu/Industry/case-studies/urate-oxidase/urate-oxidase-1>
7. Valmas A. et al., *Acta Cryst. D71*, 819 (2015).
8. ESRFNews March 2015, <https://drive.google.com/file/d/0B8B9t1F96bWKVWxsS0IjMkdUZ0U/view>
9. Karavassili et al., *Acta Cryst. D68*, 1632 (2012); Karavassili et al., *Acta Cryst. D76*, 4, 375-384 (2020).
10. Collins I. et al., *Acta Cryst. D 66*, 539 (2010).
11. Spiliopoulou M. et al., *Acta Cryst. A77*, 186-195 (2021) & [Scientific Highlights of the Paul Scherrer Institute \(PSI- Switzerland\)](#); Spiliopoulou et al., *Crystals* **10**, 54 (2020) ([Invited review article for Crystals Special Issue "Crystallization under special and physical environments"](#)).